Table 1 Characteristics of patients treated with ePTFE spacer placement surgery for SMPT
|  | No. of patients (n = 131) |
|---|---|
Age, years, median (range) | 60 (18–82) |
Gender, n (%) | Â |
Male | 63 (48.1) |
Female | 68 (51.9) |
Objects of SMPT, n (%) | Â |
Hepatocellular carcinoma | 10 (7.6) |
Hilar cholangiocarcinoma | 6 (4.6) |
Pancreas cancer | 11 (8.4) |
Metastatic liver tumor | 2 (1.5) |
Local recurrence of rectal cancer | 21 (16.0) |
Chordoma | 28 (21.4) |
Chondrosarcoma | 7 (5.3) |
Sarcoma | 31 (23.7) |
Rectal gastrointestinal stromal tumor | 1 (0.8) |
Gynecological cancer | 9 (6.9) |
Urological cancer | 2 (1.5) |
Others | 3 (2.3) |
Dose fraction, n (%) | Â |
50.0 GyE/25 fr | 3 (2.3) |
64.0 GyE/8 fr | 7 (5.3) |
64.0 GyE/16 fr | 2 (1.5) |
67.5 GyE/25 fr | 6 (4.6) |
70.2 GyE/26 fr | 6 (4.6) |
70.4 GyE/16 fr | 30 (22.9) |
70.4 GyE/32 fr | 35 (26.7) |
72.6 GyE/22 fr | 2 (1.5) |
74.0 GyE/37 fr | 12 (9.2) |
76.0 GyE/20 fr | 9 (6.9) |
76.0 GyE/38 fr | 2 (1.5) |
80.0 GyE/20 fr | 3 (2.3) |
Others | 13 (9.9) |
Discontinuation | 1 (0.8) |
Beam type, n (%) | Â |
Carbon ion | 46 (35.1) |
Proton | 85 (64.9) |